ArticleJournal of advanced research2026
Lactobacillus johnsonii-derived extracellular vesicles carrying GAPDH protect against ulcerative colitis through modulating macrophage polarization.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Probiotic extracellular vesicles reprogram macrophage immunometabolism: From gut crosstalk to host health.Gut microbes · 2026Review
- ROS-responsive small-molecule self-assembled nanocarrier-integrated hydrogels for ulcerative colitis treatment.Materials today. Bio · 2026Article
- Extracellular Vesicles from Lactic Acid Bacteria: Emerging Postbiotic Effectors in Host-Microbe Crosstalk.Probiotics and antimicrobial proteins · 2026Review
- Article
- Engineering Extracellular Vesicles for Anti-Aging Therapy: Mechanisms, Applications, and Perspectives.Aging cell · 2026Review
- miR-9394b from Lactobacillus paracasei extracellular vesicles targets iNOS to reprogram host NO-ornithine metabolism and ameliorate DSS-induced murine colitis.NPJ biofilms and microbiomes · 2026Article
- Faecalibacterium prausnitzii-derived extracellular vesicles ameliorate experimental colitis through regulating barrier immunity and gut microbiota.NPJ science of food · 2026Article
- Lactobacillus johnsonii-derived extracellular vesicles modulate gut microbiota metabolites and macrophage-related immune responses against Salmonella Typhimurium infection.Veterinary research · 2026Article
- Dietary fiber deficiency exacerbates intestinal inflammation via miR-6240-enriched gut extracellular vesicles.NPJ biofilms and microbiomes · 2026Article
- Article
- Engineered bacterial extracellular vesicles as next-generation precision postbiotics: strategies, challenges and prospects.Extracellular vesicles and circulating nucleic acids · 2026Review
- Exploring the Anti-Inflammatory Molecular Mechanism of Gentiana szechenyii Kanitz. Based on UPLC-MS/MS Combined With Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation.Chemistry & biodiversity · 2026Article
- Strain-resolved biology ofFrontiers in veterinary science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionUlcerative colitis (UC) is a major inflammatory condition worldwide.
objectivesThe purpose of this study was to investigate the potential contribution of Lactobacillus johnsonii against UC from the perspective of gut microbiota-macrophage-host interactions.
methodsL. johnsonii abundance in UC patients and colitis mice was evaluated by genomic sequencing. SPF and macrophage-depleted mice were employed to explore the effects of L. johnsonii and its products on colitis. An in vitro macrophage and intestinal epithelial cell co-culture system was constructed. Proteins in extracellular vesicles (EVs) were identified by proteomic analyses, and host signaling pathways were analyzed with transcriptomic analyses.
resultsL. johnsonii abundance was found to be associated with macrophage polarization and intestinal barrier function in human UC patients and mice of a colitis model. L. johnsonii and its derived EVs alleviate colitis in mice in a macrophage-dependent manner. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a protein in EVs derived from L. johnsonii, counteracts colitis in vitro and in vivo by regulating macrophage phenotype. GAPDH enhances anti-inflammatory macrophage polarization by inhibiting the MAPK-STAT3 axis. Macrophage-secreted EVs enhances intestinal barrier function in colitis mice by blocking the TLR4 pathway. Protein components in macrophage-derived EVs contribute to colitis remission and intestinal barrier protection.
conclusionGAPDH originating in L. johnsonii-derived EVs alleviates colitis and improves intestinal barrier by inhibiting STAT3 in macrophages. EVs created from L. johnsonii are a potential novel treatment strategy for UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.